Biotech Values

[jbog]

Dew,

As I've mentioned before I've been a Teva Holder for close to 20 years.

I have to admit that I've never followed their calls closely, but I never ever recall Teva being scrutinized about a pending application by the analysts as they are with lovenox.

While any lovenox sales for Teva would be somewhat meaningful, maybe amounting to the low single digits of 4%-6% the contribution to their bottom line would be a rounding off error.

Is the Street questioning Teva so relentlessly because they see their dominance being challenged, because of Copaxone or because of Momenta?

Secondly, why did Teva drop today if they had all the answers the street wanted?